type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial. Pancreas 2014 38. Lando HM, Alattar M, Dua AP: Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract 18:472-477, 2012 Table 1 Demographic and baseline characteristics Liraglutide 1.8 mg Placebo (N=140) (N=137) Sex, n, (%) Female 65 (46.4) 72 (52.6) Male 75 (53.6) 65 (47.4) Age, years, mean (SD) 68.0 (8.3) 66.3 (8.0) Age group, n (%) 18-64 years 38 (27.1) 55 (40.1) 65-74 years 72 (51.4) 66 (48.2) >75 years 30 (21.4) 16 (11.7) Duration of diabetes, years, mean (SD) 15.9 (8.9) 14.2 (7.5) Race, n (%) White 123 (87.9) 129 (94.2) Black or African American 14 (10.0) 4 (2.9) Asian non-Indian 2 (1.4) 1 (0.7) Asian Indian 1 (0.7) 0 Native Hawaiian or other Pacific Islander 0 1 (0.7) Other 0 2 (1.5) Insulin treatment, n (%)
type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial. Pancreas 2014 38. Lando HM, Alattar M, Dua AP: Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract 18:472-477, 2012 Table 1 Demographic and baseline characteristics Liraglutide 1.8 mg (N=140) Placebo (N=137) Sex, n, (%) Female Male 65 (46.4) 75 (53.6) 72 (52.6) 65 (47.4) Age, years, mean (SD) 68.0 (8.3) 66.3 (8.0) Age group, n (%) 18-64 years 65-74 years >75 years 38 (27.1) 72 (51.4) 30 (21.4) 55 (40.1) 66 (48.2) 16 (11.7) Duration of diabetes, years, mean (SD) 15.9 (8.9) 14.2 (7.5) Race, n (%) White Black or African American Asian non-Indian Asian Indian Native Hawaiian or other Pacific Islander Other 123 (87.9) 14 (10.0) 2 (1.4) 1 (0.7) 0 0 129 (94.2) 4 (2.9) 1 (0.7) 0 1 (0.7) 2 (1.5) Insulin treatment, n (%)
Full%20clean%20version%20Diabetes_Care_Davies_3916_maintext_refman_R2_20August2015.docx